Teijin records impairment loss and gain on share sale
Impairment loss of 25.4 billion yen on diabetes drug assets; gain of around 45.5 billion yen from selling DuPont Teijin Advanced Papers shares.
See the latest news and media coverage for Teijin. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global materials and healthcare technology group
teijin.comLast updated
In short: Teijin completed the TA Frontier merger and announced new cell-therapy and JACEMIN distribution partnerships.
Impairment loss of 25.4 billion yen on diabetes drug assets; gain of around 45.5 billion yen from selling DuPont Teijin Advanced Papers shares.
Operating income forecast revised to a loss of 75-85 billion yen due to impairment and tax adjustments.
The absorption-type merger will create a joint venture by October 2026, combining their textile businesses.
The company lowered adjusted operating income forecast by 10 billion yen and recorded 48.4 billion yen impairment loss on aramid business fixed assets due to competition and forex impact.
Teijin Limited reported earnings results for the half year ended September 30, 2026. For the half year, the company reported sales was JPY 439,562 million...
Teijin Limited announced its financial results for the first quarter ended June 30, 2026. For this first quarter, the company recorded a...
Shimai, Financial Officer/CFO, Teijin Limited: I will now explain the fiscal 2025 results and fiscal 2026 earnings outlook. First, regarding key points from the earnings...
I will now explain the fiscal 2025 results and fiscal 2026 earnings outlook. First, regarding key points from the earnings announcement, fiscal 2025 adjusted operating...
Track Teijin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Teijin and other trending companies.